LeMaitre Vascular (LMAT) CFO granted new dividend equivalent rights

Rhea-AI Filing Summary

LeBlanc Dorian Paul reported acquisition or exercise transactions in this Form 4 filing.

LeMaitre Vascular Chief Financial Officer Dorian Paul LeBlanc received additional dividend equivalent rights tied to existing restricted stock unit awards. On March 26, 2026, he was granted 2.0948 dividend equivalent rights related to an RSU award granted on March 10, 2025 and 2.6670 rights related to an RSU award granted on December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying RSUs. Following these awards, his holdings from these grants increased to 11.4217 and 2.6670 dividend equivalent rights, respectively.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider LeBlanc Dorian Paul

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Dividend Equivalent Rights	2.095	$0.00	--
Grant/Award	Dividend Equivalent Rights	2.667	$0.00	--

Holdings After Transaction: Dividend Equivalent Rights — 11.422 shares (Direct)

Footnotes (1)

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 3/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Key Figures

Dividend equivalent rights granted (3/10/2025 RSU): 2.0948 rights Dividend equivalent rights granted (12/10/2025 RSU): 2.6670 rights Total rights after transaction (3/10/2025 RSU): 11.4217 rights +3 more

6 metrics

Dividend equivalent rights granted (3/10/2025 RSU) 2.0948 rights Granted March 26, 2026

Dividend equivalent rights granted (12/10/2025 RSU) 2.6670 rights Granted March 26, 2026

Total rights after transaction (3/10/2025 RSU) 11.4217 rights Post-transaction holding

Total rights after transaction (12/10/2025 RSU) 2.6670 rights Post-transaction holding

Underlying common stock per right 1 share equivalent Each right equals one common share economically

Transaction price per right $0.0000 Grant price for rights

Key Terms

Dividend Equivalent Rights, restricted stock unit award, economic equivalent

3 terms

Dividend Equivalent Rights financial

"These dividend equivalent rights accrued on a restricted stock unit award granted on 3/10/2025"

Dividend equivalent rights are promises that mirror the cash payments shareholders get from a company’s profits, but they are paid to holders of certain awards (like stock options or restricted stock units) rather than to actual shares. Think of them as a paycheck top‑up that matches dividends while the award is not yet a real stock, and they matter to investors because they add to employee compensation costs and potential share dilution, affecting company profitability and per‑share value.

restricted stock unit award financial

"These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

economic equivalent financial

"Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeBlanc Dorian Paul

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MASSACHUSETTS 01803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	03/26/2026		A		2.0948		(1)	(1)	Common Stock	2.0948	$0	11.4217	D
Dividend Equivalent Rights	(2)	03/26/2026		A		2.667		(2)	(2)	Common Stock	2.667	$0	2.667	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 3/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Laurie A. Churchill, Attorney-in-fact	03/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did LeMaitre Vascular (LMAT) disclose in this Form 4 for Dorian Paul LeBlanc?

LeMaitre Vascular reported that CFO Dorian Paul LeBlanc received grants of dividend equivalent rights on March 26, 2026. These rights are tied to prior restricted stock unit awards and mirror the value of common stock dividends over time.

How many dividend equivalent rights did LMAT’s CFO receive in this transaction?

Dorian Paul LeBlanc received 2.0948 dividend equivalent rights tied to a March 10, 2025 RSU grant and 2.6670 rights tied to a December 10, 2025 RSU grant. Each right is economically equivalent to one share of common stock.

What are dividend equivalent rights in the context of LeMaitre Vascular (LMAT)?

For LeMaitre Vascular, dividend equivalent rights are compensation instruments that accrue on restricted stock units. Each right is the economic equivalent of one share of common stock and vests proportionately alongside the related restricted stock unit award over time.

How did this Form 4 change the CFO’s holdings of dividend equivalent rights at LMAT?

After the March 26, 2026 grants, Dorian Paul LeBlanc held 11.4217 dividend equivalent rights associated with the March 10, 2025 RSU award and 2.6670 rights associated with the December 10, 2025 RSU award, reflecting the additional accruals from these transactions.

Are the dividend equivalent rights reported by LMAT’s CFO considered open-market share purchases?

No, the dividend equivalent rights granted to LeMaitre Vascular’s CFO are part of equity compensation linked to restricted stock units. They are recorded as grant or award acquisitions, not open-market share purchases or sales on an exchange.